received no comments on the draft guidance. The guidance announced in this notice finalizes the draft guidance dated June 2015.

# II. Significance of Guidance

This level 1 guidance is being issued consistent with FDA's good guidance practices regulation (21 CFR 10.115). The guidance represents the current thinking of FDA on oncology drugs for companion animals. It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. This guidance is not subject to Executive Order 12866.

# III. Paperwork Reduction Act of 1995

This guidance refers to previously approved collections of information found in FDA regulations. These collections of information are subject to review by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995 (44 U.S.C. 3501–3520). The collections of information in 21 CFR 514.1 and 514.8 have been approved under OMB control number 0910–0032.

### IV. Electronic Access

Persons with access to the internet may obtain the guidance at either https://www.fda.gov/AnimalVeterinary/GuidanceComplianceEnforcement/GuidanceforIndustry/default.htm or https://www.regulations.gov.

Dated: August 18, 2017.

### Leslie Kux,

Associate Commissioner for Policy. [FR Doc. 2017–17855 Filed 8–22–17; 8:45 am]

BILLING CODE 4164-01-P

# DEPARTMENT OF HEALTH AND HUMAN SERVICES

## **Food and Drug Administration**

[Docket Nos. FDA-2013-N-0804; FDA-2013-N-1163; FDA-2013-N-1393; FDA-2017-N-0084; FDA-2013-N-0731; FDA-2009-D-0008; FDA-2013-N-0868; FDA-2013-D-0117; FDA-2016-N-2066; FDA-2017-N-0366]

Agency Information Collection Activities; Announcement of Office of Management and Budget Approvals

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Food and Drug Administration (FDA) is publishing a list of information collections that have been approved by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995.

FOR FURTHER INFORMATION CONTACT: Ila S. Mizrachi, FDA PRA Staff, Office of Operations, Food and Drug Administration, Three White Flint North, 11601 Landsdown St., North Bethesda, MD 20852, 301–796–7726, PRAStaff@fda.hhs.gov.

SUPPLEMENTARY INFORMATION: The following is a list of FDA information collections recently approved by OMB under section 3507 of the Paperwork Reduction Act of 1995 (44 U.S.C. 3507). The OMB control number and expiration date of OMB approval for each information collection are shown in table 1. Copies of the supporting statements for the information collections are available on the internet at https://www.reginfo.gov/public/do/ PRAMain. An Agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number.

## TABLE 1-LIST OF INFORMATION COLLECTIONS APPROVED BY OMB

Title of collection	OMB control No.	Date approval expires
Premarket Notification Submission 510(k), Subpart E	0910-0120	6/30/2020
Institutional Review Boards	0910-0130	6/30/2020
Patent Term Restoration, Due Diligence Petitions, Filing, Format, and Content of Petitions	0910-0233	6/30/2020
Adverse Event Program for Medical Devices (Medical Product Safety Network (MedSun))	0910-0471	6/30/2020
Eligibility Determination for Donors of Human Cells, Tissues, and Cellular and Tissue-Based Products	0910–0543	6/30/2020
Cosmetic Act	0910–0679	6/30/2020
Guidance for Industry: Use of Serological Tests to Reduce the Risk of Transmission of <i>Trypanosoma cruzi</i> Infection in Whole Blood and Blood Components Intended for Transfusion	0910–0681	6/30/2020
Drug, and Cosmetic Act	0910-0762 0910-0832 0910-0833	6/30/2020 6/30/2020 6/30/2020

Dated: August 18, 2017.

### Leslie Kux,

Associate Commissioner for Policy.
[FR Doc. 2017–17871 Filed 8–22–17; 8:45 am]

BILLING CODE 4164-01-P